What Is the Role of PK/PD Studies in Biosimilar Development and Can They Replace Clinical Efficacy Trials?
Introduction: The role of PK/PD studies in biosimilar development has become one of the most closely watched questions in biologics […]
Reference Product Selection and Sourcing Strategy for Biosimilar Comparability Studies
Introduction: Establishing structural and functional similarity to an approved innovator biologic represents the cornerstone of regulatory approval for biosimilar products
Reference Product Selection and Sourcing Strategy for Biosimilar Comparability Studies Read More »
Case Study: Using the Multi-Attribute Method (MAM) to Streamline Biosimilar Lot Release Testing
Introduction: Biosimilar development is analytically demanding. Regulatory agencies — Health Canada, the FDA, and the EMA alike — require manufacturers
Immunogenicity Assessment in Biosimilar Development: Regulatory Strategy and Testing Approaches
Introduction: Why Immunogenicity Assessment in Biosimilar Development Is Non-Negotiable Immunogenicity assessment in biosimilar development refers to the structured process of
Cell Line Development for Biosimilars: Choosing the Right Expression System and Clone Selection Strategy
Introduction to Biosimilar Cell Line Engineering In the biopharmaceutical industry, Cell Line Development for Biosimilars is a highly regulated, comparability-driven
Why Do Some Biosimilars Fail Regulatory Approval? The Most Common Development Pitfalls
Understanding Why Biosimilars Fail Regulatory Approval: An Analytical Overview Biosimilars fail regulatory approval primarily because of deficiencies in chemistry, manufacturing,
Why Do Some Biosimilars Fail Regulatory Approval? The Most Common Development Pitfalls Read More »
What Analytical Tests Are Mandatory for a Biosimilar Regulatory Submission?
Introduction: Understanding which analytical tests for biosimilar regulatory submission are mandatory is one of the most complex challenges in biologic drug development.
What Analytical Tests Are Mandatory for a Biosimilar Regulatory Submission? Read More »
LC-MS/MS Services for Biosimilar Comparability Studies
Introduction to Advanced Biosimilar Comparability Demonstrating analytical similarity is the cornerstone of biosimilar development, serving as the primary step in
LC-MS/MS Services for Biosimilar Comparability Studies Read More »
Biosimilar Aggregation and Particle Analysis Service: SEC-MALS, DLS, and MFI Explained
Introduction Biosimilar Aggregation Analysis sits at the center of every biosimilar comparability program, because protein aggregates — whether a few
Biosimilar Aggregation and Particle Analysis Service: SEC-MALS, DLS, and MFI Explained Read More »
Biosimilar Formulation Development Service: Stability, Excipient Screening, and Shelf-Life Studies
Advanced Optimization in Biosimilar Formulation Development Service Stability A comprehensive biosimilar formulation development service stability program is designed to ensure